首页> 外文期刊>Neurology Research International >Multimodal MRI Neuroimaging Biomarkers for Cognitive Normal Adults, Amnestic Mild Cognitive Impairment, and Alzheimer's Disease
【24h】

Multimodal MRI Neuroimaging Biomarkers for Cognitive Normal Adults, Amnestic Mild Cognitive Impairment, and Alzheimer's Disease

机译:适用于认知正常成年人,轻度遗忘性认知障碍和阿尔茨海默氏病的多模式MRI神经成像生物标志物

获取原文
       

摘要

Multimodal magnetic resonance imaging (MRI) techniques have been developed to noninvasively measure structural, metabolic, hemodynamic and functional changes of the brain. These advantages have made MRI an important tool to investigate neurodegenerative disorders, including diagnosis, disease progression monitoring, and treatment efficacy evaluation. This paper discusses recent findings of the multimodal MRI in the context of surrogate biomarkers for identifying the risk for AD in normal cognitive (NC) adults, brain anatomical and functional alterations in amnestic mild cognitive impairment (aMCI), and Alzheimer's disease (AD) patients. Further developments of these techniques and the establishment of promising neuroimaging biomarkers will enhance our ability to diagnose aMCI and AD in their early stages and improve the assessment of therapeutic efficacy in these diseases in future clinical trials.
机译:已经开发出多峰磁共振成像(MRI)技术来无创地测量大脑的结构,代谢,血液动力学和功能变化。这些优点使MRI成为研究神经退行性疾病的重要工具,包括诊断,疾病进展监测和治疗效果评估。本文讨论了替代生物标志物背景下多模态MRI的最新发现,这些生物标志物用于识别正常认知(NC)成人的AD风险,健忘性轻度认知障碍(aMCI)和阿尔茨海默氏病(AD)患者的脑解剖和功能改变。这些技术的进一步发展和有前途的神经影像生物标志物的建立将增强我们在早期诊断aMCI和AD的能力,并在未来的临床试验中改善对这些疾病的治疗效果评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号